The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart.
This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.
aged 18 years or older at screening of the previous study and completed the required treatment duration with PF-07868469 and other assessments at the end of that study.
willing and able to abide with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
do not have worsening or hospitalization for worsening PAH during the qualifying study.
not on placement for a surgery to replace any tissue or part of the body (transplant), and planned surgery for PAH.
None
Single group
PF-07868489
DrugParticipants will receive subcutaneous doses of PF-07868489 every 4 weeks
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of Participants With Change From Baseline in Laboratory Tests Results
Number of Participants With Vital Sign Abnormalities
Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters
Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration
Minimum Observed Plasma Trough Concentration (Cmin), as data permits
Incidence of Anti-Drug Antibody (ADA)
